Compare Neurocrine Biosciences Inc (NBIX) vs Peloton Interactive Inc (PTON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Peloton Interactive Inc — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Peloton Interactive Inc trades at $5.06 (market cap $2.21B). The key difference: Neurocrine Biosciences Inc is far larger — about 7.1× Peloton Interactive Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Peloton Interactive Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | PTON | |
|---|---|---|
Market Cap | $15.77B | $2.21B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $9.00 |
52-Week Low | $123.10 | $3.71 |
Enterprise Value | $15.78B | $2.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Peloton Interactive (PTON) trades at $5.04, down 6.67% amid bearish technical signals and mixed fundamentals. The company achieved its first full-year net profit in fiscal 2026 with a 2.58% net income margin, though revenue declined to $2.49B in 2025. Analyst sentiment is divided with a 50% buy rating but a consensus price target of $7.25, while technical indicators show strong bearish momentum with all moving averages signaling sell.
The outlook remains cautious as PTON balances profitability gains against subscriber declines and weak revenue growth. Investment opportunity exists if cost-cutting sustains margins, but risks include high debt load, competitive pressures, and insider selling activity. The stock trades near key support levels with institutional sentiment mixed.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →
